Bystedt H
Int J Oral Surg. 1976 Apr;5(2):66-70. doi: 10.1016/s0300-9785(76)80050-6.
The clinical effect of Rheumapax and placebo on postoperative complications after surgical removal of the impacted mandibular third molar has been evaluated in a controlled clinical trial. The investigation included 66 patients in two treatment groups, 32 patients being given Rheumapax and 34 placebo. Hematological tests performed before and 10 days after the operation revealed no adverse reactions. There was a significant reduction of postoperative pain and trismus with Rheumapax in addition to a favorable, through nonsignificant, effect on swelling.
在一项对照临床试验中,评估了瑞莫派克斯(Rheumapax)和安慰剂对下颌阻生第三磨牙拔除术后并发症的临床疗效。该研究纳入了两个治疗组的66例患者,其中32例患者服用瑞莫派克斯,34例服用安慰剂。术前及术后10天进行的血液学检查未发现不良反应。瑞莫派克斯可显著减轻术后疼痛和牙关紧闭,对肿胀也有良好但不显著的效果。